Pickart estimated lethal dose at approximately 22,500 mg for humans (300-fold above effective doses), with animal LD50 studies in mice showing 8 mg per 25g mouse (320 mg/kg, translating to ~22,400 mg for 154 lb human)
Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury
For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog
Collectively, tripeptides represent a promising class of multifunctional bioactive molecules in wound care, offering novel avenues for targeted tissue regeneration
[7] Each subunit interacts with each other through alpha helix and beta sheet hydrogen bonding interactions and contains two domains
The sparse evidence for most injectable peptides means we have very little data on side effects